Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-20 07:30 |
Spexis announces business update call to be held on July 28th
|
English | 9.6 KB | ||
| 2022-07-20 02:00 |
Spexis announces business update call to be held on July 28th
|
English | 7.6 KB | ||
| 2022-07-20 02:00 |
Spexis kündigt für den 28. Juli ein Update zur Geschäftsentwicklung an
|
German | 7.9 KB | ||
| 2022-07-07 07:30 |
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in comb…
|
English | 11.3 KB | ||
| 2022-07-07 02:00 |
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in comb…
|
English | 9.2 KB | ||
| 2022-07-07 02:00 |
Spexis' CXCR4 Inhibitor Balixafortide zeigt synergistische Wirksamkeit in Kombi…
|
German | 10.3 KB | ||
| 2022-05-19 07:30 |
Spexis to present at H.C. Wainwright Global Investment Conference
|
English | 7.8 KB | ||
| 2022-05-12 08:37 |
Spexis to present at BioEquity Europe 2022
|
English | 14.2 KB | ||
| 2022-05-12 07:30 |
Spexis to present at BioEquity Europe 2022
|
English | 7.6 KB | ||
| 2022-04-27 09:20 |
Annual General Meeting
|
English | 13.1 KB | ||
| 2022-04-27 07:15 |
Spexis Annual General Meeting 2022
|
English | 8.0 KB | ||
| 2022-04-01 09:11 |
Annual General Meeting 2022
|
English | 15.7 KB | ||
| 2022-04-01 07:00 |
Spexis publishes invitation to Annual General Meeting 2022
|
English | 9.6 KB | ||
| 2022-03-24 09:12 |
Financial results for the full-year 2021
|
English | 27.1 KB | ||
| 2022-03-24 07:15 |
Spexis provides business update and announces financial results for the full-ye…
|
English | 20.6 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
